Acinetobacter baumannii is a significant public health threat due to its virulence and ability to cause epidemics. Its capacity to form biofilms and survive in harsh environmental conditions poses challenges in healthcare settings, facilitating the spread and severity of
A. baumannii infections (
26,
27). The AMPs are versatile immune molecules that can serve as potential alternatives to conventional antibiotics, though their natural forms are limited by susceptibility to proteolytic degradation (
28). To address the limitations of natural AMPs, researchers have focused on designing and synthesizing shorter, optimized peptide sequences that exhibit enhanced antimicrobial activity and reduced toxicity, a promising approach for discovering and developing effective antimicrobial agents (
29).
The present study further evaluated the in vitro and in vivo efficacy of the peptide M-PEX12, which demonstrated a greater than 95% reduction in the
A. baumannii population when exposed for 30 minutes at concentrations corresponding to 1x and 2x MIC. The rapid killing kinetics of M-PEX12 against
A. baumannii, c
ompArable to other AMPs, may be attributed to its dual mechanisms of action involving both membrane disruption and interaction with intracellular targets. In a study by Prada-Prada et al., the newly designed AMP Ib-M exhibited a greater than 95% reduction in the
E. coli O157:H7 population after a 4-hour exposure at 1x MIC (
30).
This study found that the antibacterial agent M-PEX12 can potentially induce the excessive generation of ROS, including hydrogen peroxide (H
2O
2), hydroxyl radical (OH
-), singlet oxygen (O
2), and superoxide anion (O
2–), in
A. baumannii bacteria (
31). The increased levels of ROS can damage bacterial proteins, lipids, and nucleotides, leading to programmed cell death. Although bacteria have some tolerance to ROS due to antioxidative stress response genes (
32), M-PEX12 can induce a lethal level of oxidative stress that overwhelms the bacterial defense mechanisms, ultimately resulting in the death of the
A. baumannii cells.
Taken together, the M-PEX12 AMP exhibits effective anti-biofilm activity against
A. baumannii ATCC 19606 through various mechanisms, including disrupting bacterial membranes, interfering with cell signaling, and degrading the extracellular matrix, resulting in a dose-dependent inhibition of biofilm formation (
33). Molecular dynamics simulations (previous study) and SEM analysis revealed that M-PEX12, with its physicochemical properties of short chain, α-helix, net positive charge, and amphipathic nature, disrupts bacterial membranes and alters the surface morphology of
A. baumannii, leading to pore formation and significant damage, without exhibiting toxicity against host cells. In a study by Wang et al., synthetic peptides derived from butterflies exhibited antimicrobial effects by causing significant changes in the structure and properties of microbial cell membranes and nuclei, suggesting their ability to penetrate cell membranes and interact with nucleic acids (
34).
In vitro assessments showed that the AMP M-PEX12 exhibited a favorable cytotoxicity profile, maintaining high viability of HEK293 cells even at concentrations exceeding its minimum inhibitory concentration (MIC and twice the MIC of M-PEX12), suggesting its potential as a promising antimicrobial agent. The hemolysis assay results showed that M-PEX12 exhibited minimal hemolytic activity at the MIC concentration (0.72%) and a slightly higher level at 2x MIC (1%), supporting the safety profile of M-PEX12 and its potential for in vivo evaluation of efficacy against A. baumannii infection in a mouse model.
The study found that treating
A. baumannii with the M-PEX12 peptide led to a significant decrease in the expression of virulence genes, likely due to the peptide's ability to penetrate bacterial cells and interact with nucleic acids and intracellular proteins, consistent with previous research by Liu et al. on the impact of AMPs on virulence gene expression (
20). The study found that while the AMP M-PEX12 and the antibiotic meropenem both showed significant reductions in
A. baumannii bacterial counts and improved survival in a mouse model, meropenem was more effective, suggesting further investigation is needed to enhance the efficiency of M-PEX12, potentially by optimizing the modifications made to the parent peptide sequence during the hybridization process.
The study by Nagarajan et al. found that unlike the antibiotic colistin, the AMP Ω76 does not possess nephrotoxic properties, suggesting Ω76 has potential to be used as an alternative or adjunctive therapy to colistin in clinical settings (
25). The study by Jung et al. found that the AMPs SMAP-29, TP4, and its derivatives dN4 and dC4 exhibited prophylactic and therapeutic effects against
A. baumannii-induced pneumonia, including the ability to inhibit and eliminate
A. baumannii biofilms, suggesting their potential as treatment strategies (
35). These findings validate the outcomes of the in vitro investigations and provide evidence that M-PEX12 holds significant promise for being formulated into an effective antimicrobial therapeutic agent.
Based on the statistical results of the conducted tests and the significant differences observed compAred to the control group (P < 0.05), the M-PEX12 peptide has the potential to effectively control the target bacteria. While the results with M-PEX12 are promising, several limitations must be acknowledged. The small sample size in our in vivo experiments may restrict the generalizability of our findings. Additionally, the specific strains of A. baumannii used may not fully represent the diversity encountered in clinical settings. Although our in vitro results are encouraging, the in vivo environment poses additional challenges that could affect M-PEX12's efficacy. The selection of strains and testing conditions may introduce biases, even though we aimed to minimize this by using well-characterized strains. Lastly, variations in environmental factors, such as temperature and pH, could influence outcomes despite our efforts to standardize these conditions.
In summary, our study introduces a novel approach to the design and prediction of AMPs. The peptides generated using our method demonstrated effective antibacterial activity in both laboratory experiments (in vitro) and living organisms (in vivo). However, it is important to acknowledge that synthetic peptides may not exhibit identical behavior in computational simulations (in silico) and laboratory investigations, as emphasized by our findings. Despite M-PEX12 exhibiting lower efficacy compAred to certain antibiotics against A. baumannii, it holds promise as an alternative treatment for A. baumannii infections, particularly considering the high prevalence of antibiotic resistance. These findings have significant implications for future research in the development and application of innovative antimicrobial therapies.